Last Updated: June 25, 2026

List of Excipients in API amlodipine and olmesartan medoxomil


✉ Email this page to a colleague

« Back to Dashboard


Excipients in ANDA-approved (generic) drugs containing amlodipine and olmesartan medoxomil

Company Ingredient NDC Excipient
Torrent Pharmaceuticals Limited amlodipine and olmesartan medoxomil 13668-324 CROSCARMELLOSE SODIUM
Torrent Pharmaceuticals Limited amlodipine and olmesartan medoxomil 13668-324 LACTOSE MONOHYDRATE
Torrent Pharmaceuticals Limited amlodipine and olmesartan medoxomil 13668-324 MAGNESIUM STEARATE
>Company >Ingredient >NDC >Excipient

Subscribe to access the full database, or Start Trial

Detailed excipient profiles for amlodipine and olmesartan medoxomil

Excipient focus: ANHYDROUS LACTOSE

Excipient focus: CELLULOSE, MICROCRYSTALLINE

Excipient focus: CROSCARMELLOSE SODIUM

Excipient focus: CROSPOVIDONE

Excipient focus: FD&C RED NO. 40

Excipient focus: FD&C YELLOW NO. 6

Excipient focus: FERRIC OXIDE RED

Excipient focus: FERRIC OXIDE YELLOW

Excipient focus: HYDROGENATED CASTOR OIL

Excipient focus: HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED

Excipient focus: HYPROMELLOSES

Excipient focus: LACTOSE MONOHYDRATE

Excipient focus: MAGNESIUM STEARATE

Excipient focus: MICROCRYSTALLINE CELLULOSE 102

Excipient focus: POLYETHYLENE GLYCOL

Excipient focus: POLYETHYLENE GLYCOL 3000

Excipient focus: POLYETHYLENE GLYCOL 3350

Excipient focus: POLYETHYLENE GLYCOL 400

Excipient focus: POLYETHYLENE GLYCOL 4000

Excipient focus: POLYETHYLENE GLYCOL 8000

Excipient focus: POLYVINYL ALCOHOL

Excipient focus: POVIDONE K30

Excipient focus: POWDERED CELLULOSE

Excipient focus: SILICA

Excipient focus: SILICON DIOXIDE

Excipient focus: SODIUM STARCH GLYCOLATE TYPE A POTATO

Excipient focus: STARCH, CORN

Excipient focus: STEARIC ACID

Excipient focus: SUCCINIMIDYL-4-(N-MALEIMIDOMETHYL)CYCLOHEXANE-1-CARBOXYLATE

Excipient focus: TALC

Excipient focus: TITANIUM DIOXIDE

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links